Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 7/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758370 | 0.89 | KCNH2 (0.58) | SLC2A1KCNH2 | |
| SCHEMBL14519825 | 0.89 | SLC2A1 (0.76) | SLC2A1KCNH2ACHE | |
| SCHEMBL13014300 | 0.86 | SLC2A1 (0.55) | SLC2A1KCNH2KCNJ1 | |
| SCHEMBL3775156 | 0.85 | KCNH2 (0.79) | SLC2A1KCNH2 | |
| SCHEMBL4760076 | 0.84 | KCNH2 (0.57) | SLC2A1KCNH2HTR7 | |
| SCHEMBL3786610 | 0.82 | KCNH2 (0.74) | SLC2A1KCNH2 | |
| SCHEMBL3779600 | 0.81 | KCNH2 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL3775094 | 0.81 | KCNH2 (0.53) | SLC2A1KCNH2KCNJ1 | |
| SCHEMBL13014304 | 0.81 | SLC2A1 (0.55) | SLC2A1NPC1RAB9ADRD4 | |
| SCHEMBL3769272 | 0.80 | SLC2A1 (0.53) | SLC2A1KCNH2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | SLC2A1 4605/4885KCNH2 3216/4885ACHE 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.